• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002275.SZ
Share

Guilin Sanjin Pharmaceutical Co., Ltd. Stocks

CN¥ 13.26Last Updated 21.07.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

CN¥ 1.16B

CN¥ 13.26
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guilin Sanjin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the research, production, and distribution of traditional Chinese and natural medicines across China. Established in 1967 and headquartered in Guilin, the company's product portfolio prominently features well-known traditional Chinese medicine (TCM) brands such as Guilin watermelon frost and lozenge, Sanjin tablets, and Naomaitai capsules. Beyond these core offerings, it also manufactures a range of other TCM preparations. The company operates as a subsidiary of the broader Guilin SanJin Group Co.,Ltd.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.07.2026 19:15

Neuronetics, a company that develops treatments for depression, saw its stock price rise by 25%. What happened?

21.07.2026 18:54

The U.S. president may impose new tariffs on dozens of countries this week — FT

21.07.2026 18:18

Chinese AI models have caught up with their American counterparts. Will Beijing now restrict access to them?

21.07.2026 17:58

The Houthis have threatened to attack any ships that enter Saudi Arabian ports

21.07.2026 17:37

Kazakhstan to Suspend Oil Shipments to Its Main Export Terminal — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026